Who is sponsoring NCT00359814?

NCT00359814 is sponsored by Hannover Medical School.

What drugs are being tested in NCT00359814?

Interventions in NCT00359814: Mycophenolatmofetile, Cyclosporin A.

What condition does NCT00359814 study?

NCT00359814 studies Heart Transplantation.

Is NCT00359814 still recruiting?

NCT00359814 is currently completed. Last updated 13 February 2009.

Last reviewed 2009-02-13 · How we verify

NCT00359814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Conversion Study to Optimize Immunosuppressive Regimen by Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction for Patients After Heart Transplantation in Lon-Term

Completed NA Last updated 13 February 2009

What this trial tests

NA trial testing Mycophenolatmofetile in Heart Transplantation in 23 participants. Completed in 1 June 2008.

Timeline

1 November 2004

Primary endpoint
1 June 2008

1 June 2008

Quick facts

Lead sponsor	Hannover Medical School
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	1 November 2004
Primary completion	1 June 2008
Estimated completion	1 June 2008
Sites	1 location across Germany

Drugs / interventions tested

Mycophenolatmofetile — full drug profile →
Cyclosporin A — full drug profile →

Conditions studied

Heart Transplantation — all drugs for Heart Transplantation →

Sponsor

Hannover Medical School

Who can join

Adults 18 to 75, any sex, with Heart Transplantation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Renal function evaluated by serum creatinine at month 12 and month 24
Time frame: month 12 and month 24

Sponsor's own description

The purpose of this study is to improve or save renal function by optimizing the immunosuppressive regimen by reducing the Cyclosporine A dose and the exchange of Azathioprine by Mycophenolatmofetile, which is an effective immunosuppressive agent and will minimize the risk of acute rejection episodes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Heart Transplantation

Currently open trials in the same condition.

NCT07359690 — Multimodal Analysis of Endomyocardial Biopsies · recruiting
NCT07096973 — Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery · recruiting
NCT07372820 — METABolic Deterioration in HTX Determines Outcomes · recruiting
NCT06982404 — ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biop · recruiting
NCT07531784 — A National Swedish Study Evaluating Dd-cfDNA for as a Diagnostic Biomarker for Rejection Surveillence in Heart Transplan · recruiting

Other Hannover Medical School trials

Trials by the same sponsor.

NCT07384039 — Exercise Training in Patients With Myeloproliferative Neoplasms · NA · not yet recruiting
NCT06740747 — Intermittent Theta-Burst Stimulation to Improve Negative Symptoms and Cognition in Schizophrenia · NA · recruiting
NCT06795516 — Observational Study on the Clinical Use of ex Vivo Lung Perfusion (XPS™) for Lung Transplantation · terminated
NCT06603311 — Finite Treatment of Hepatitis Delta With Bulevirtide: Identification of Biomarkers Associated With Sustained Control of · NA · active not recruiting
NCT06493006 — Promoting Sustainable and Active Mobility Among Employees and Students · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00359814 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hannover Medical School
Last refreshed: 13 February 2009

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00359814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing